“For example, in atopic dermatitis (AD) Sanofi’s Dupixient was approved in 2017, while Benlysta was approved for systemic lupus erythematosus (SLE) in 2011,” he says. He adds that there have ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback